CYTO (Altamira Therapeutics Ltd.) Short-Term Debt to Capital

Corporate company logo of Altamira Therapeutics Ltd (CYTO)

Altamira Therapeutics (CYTO) specializes in the development of RNA transport systems. The share price history on GURU.Markets is currently recorded at 0.00. The business relies on the success of licensing agreements and the testing of anti-infective agents. The firm's innovation potential is based on the OligoPhore nanoplatform for the precise distribution of genetic code. Meanwhile, production capacities and cleanroom equipment are functioning without disruption according to the research schedule.

Ratio of Short-Term Indebtedness to Capital: altamiratherapeutics.com (CYTO) for 07/04/2022 - 01/04/2025

Analytical breakdowns for Altamira Therapeutics

- stock quotes and analyst forecast:
Stock Price Altamira Therapeutics|CYTO - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Altamira Therapeutics Ltd|CYTO - Enterprise Value
- book capitalization information:
Net Assets per Single Share Altamira Therapeutics|CYTO - Accounting Value of Company|Market Value to Book Value Ratio altamiratherapeutics.com|CYTO - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Altamira Therapeutics|CYTO - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Altamira Therapeutics|CYTO - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Altamira Therapeutics Ltd|CYTO - Long-Term Debt|Company Current Liabilities Altamira Therapeutics|Quick Ratio altamiratherapeutics.com
- company profitability and valuation multiples indicators:
CYTO - Final Profit
Fundamental valuation:CYTO Altamira Therapeutics Ltd.
Brand item of altamiratherapeutics.com

The short-term debt-to-equity ratio measures the proportion of current liabilities within the equity structure, allowing investors to identify hidden liquidity degradation and the risk of asset impairment. By analyzing the dynamics of short-term liabilities relative to equity on GURU.Markets, it can be confirmed that the ideal state of Altamira Therapeutics (CYTO) laboratories and the absence of downtime in RNA research are supported by financial stability rather than critical borrowing.

Competitors of Altamira Therapeutics (CYTO)

Short-Term Debt to Capital HLN|KVUE (Kenvue Health) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital VRNA (Verona Pharma plc)|Short-Term Debt to Capital jyongbio.com MENS|LGND - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital AMRX (Amneal Pharmaceuticals, Inc.)|Perrigo Company (PRGO) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Alvotech Biopharmaceuticals|LQDA (Liquidia Corporation) - Short-Term Debt to Capital|Short-Term Debt to Capital glpg.com|Short-Term Debt to Equity Ratio ANIP (ANI Pharmaceuticals, Inc.)|MNKD (MannKind Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Amphastar AMPH|Pacira Corp (PCRX) - Current Liabilities to Capital|SPRY: Short-Term Debt to Equity Ratio|theravance.com - Short-Term Loans to Capital Ratio|AQST: Short-Term Debt to Capital|scPharmaceuticals - Ratio of Short-Term Indebtedness to Capital|TECX (Tectonic Therapeutic Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Tonix Pharmaceuticals Holding TNXP|Short-Term Debt to Equity China SXT Pharmaceuticals (SXTC)|EPRX (eupraxiapharma.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital BHST (BioHarvest Sciences Inc.)|Short-Term Debt to Capital Invizyne Technologies EXOZ|ORMP - Short-Term Debt to Equity|ENTX: Short-Term Debt to Equity|HYFT (MindWalk Holdings) - Short-Term Debt to Equity Ratio|ABVC: Short-Term Loans to Capital Ratio|CPIX (Cumberland Pharmaceuticals Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Quantum BioPharma Ltd.|Short-Term Debt to Equity FibroGen Corp (FGEN)|Short-Term Debt to Equity Ratio Telomir Pharmaceuticals Corp TELO|Short-Term Debt to Capital RANI (Rani Therapeutics Holdings, Inc.)|Short-Term Debt to Capital Coefficient Synergy CHC Corp. (SNYR)|RLYB - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital LEXX (Lexaria Bioscience)|PULM: Short-Term Debt to Capital|Pheton Holdings (PTHL) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio APM|LYRA: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio IBO (Impact BioMedical)|Short-Term Loans to Capital Ratio TNFA|Short-Term Debt to Capital YCBD (cbdMD)|Ratio of Short-Term Indebtedness to Capital PRFX|Lipella Pharmaceuticals - Short-Term Debt to Capital|Current Liabilities to Capital optinose.com|Pieris Pharmaceuticals, Inc. (PIRS) - Short-Term Debt to Equity|Procaps Group - Ratio of Short-Term Indebtedness to Capital|PTPI (Petros) - Short-Term Debt to Capital|Short-Term Debt to Capital Qilian International Corp|Short-Term Debt to Equity Acelyrin, Inc. (SLRN)|TFFP: Current Liabilities to Equity